RenovoRx Future Growth

Future criteria checks 0/6

RenovoRx is forecast to grow earnings and revenue by 62.8% and 70.7% per annum respectively while EPS is expected to grow by 68.7% per annum.

Key information

62.8%

Earnings growth rate

68.7%

EPS growth rate

Biotechs earnings growth	23.2%
Revenue growth rate	70.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	15 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqCM:RNXT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	12	-7	N/A	N/A	2
12/31/2025	N/A	-13	N/A	N/A	2
12/31/2024	N/A	-8	N/A	N/A	2
12/31/2023	N/A	-10	-10	-10	N/A
9/30/2023	N/A	-9	-10	-10	N/A
6/30/2023	N/A	-10	-10	-10	N/A
3/31/2023	N/A	-10	-9	-9	N/A
12/31/2022	N/A	-10	-9	-9	N/A
9/30/2022	N/A	-10	-10	-10	N/A
6/30/2022	N/A	-9	-8	-8	N/A
3/31/2022	N/A	-8	-7	-7	N/A
12/31/2021	N/A	-6	-6	-6	N/A
9/30/2021	N/A	-5	-4	-4	N/A
6/30/2021	N/A	-4	-4	-4	N/A
3/31/2021	N/A	-4	-3	-3	N/A
12/31/2020	N/A	-4	-4	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RNXT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RNXT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RNXT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RNXT is forecast to have no revenue next year.

High Growth Revenue: RNXT is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RNXT's Return on Equity is forecast to be high in 3 years time

RenovoRx Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 23% to US$8.50

Price target increased by 15% to US$11.50

Price target decreased to US$10.00

Recent updates

RenovoRx, Inc., Annual General Meeting, Jun 06, 2024

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

RenovoRx, Inc. announced that it has received $11.136652 million in funding

New major risk - Negative shareholders equity

New major risk - Shareholder dilution

Renovorx, Inc. Announces Demise of David Diamond as Lead Independent Director, Chair of the Audit Committee and Member of the Compensation Committee

Renovorx Engages Oklahoma University Health as First Clinical Site in Preparation for the Pivotal Phase Iiiougar Clinical Trial in Bile Duct Cancer

RenovoRx, Inc. Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform

Renovorx Appoints Michel Ducreux as Scientific Advisory Board

Price target decreased by 23% to US$8.50

RenovoRx Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

RenovoRx, Inc. announced delayed 10-Q filing

RenovoRx, Inc Announces New Positive Interim Phase III Data Demonstrating RenovoGem(TM) Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer

RenovoRx, Inc. Appoints Margaret A.Tempero, M.D., to Scientific Advisory Board

Renovorx, Inc. Initiates Patient Enrollment At University of Texas Southwestern Medical Center for Pivotal Phase III Tiger-Pac Clinical Trial

RenovoRx, Inc. Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer

Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?

Price target increased by 15% to US$11.50

Renovorx, Inc. Announces Initial Results from A Pharmacokinetic (PK) Substudy Within the Phase III Un-Blinded Randomized Control Tiger-Pac Clinical Trial

Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky

Price target decreased to US$10.00

RenovoRx, Inc. Appoints Angela Gill Nelms as Chief Operating Officer

RenovoRx reports Q2 results

Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?

Renovorx Appoints James Ahlers as Chief Financial Officer

RenovoRx names new finance CFO

Renovorx Launches "The Renovorx Story" Video Series

RenovoRx, Inc., Annual General Meeting, Jun 09, 2022

RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans

RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing Tiger-Pac Phase 3 Clinical Trial

We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth

RenovoRx, Inc. Receives New 510(k) Clearance for its RenovoCath Delivery System Designed for Targeted Treatment of Solid Tumors

RenovoRx, Inc. has completed an IPO in the amount of $16.65 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies